Cargando…
The role of autoimmune antibodies to predict secondary autoimmunity in patients with relapsing-remitting multiple sclerosis treated with alemtuzumab: A nationwide prospective survey
BACKGROUND: Alemtuzumab (ALZ) is an immune reconstitution therapy for treating relapsing-remitting multiple sclerosis (RRMS). However, ALZ increases the risk of secondary autoimmune diseases (SADs). OBJECTIVE: We explored whether the detection of autoimmune antibodies (auto-Abs) could predict the de...
Autores principales: | Sandgren, Sofia, Novakova, Lenka, Axelsson, Markus, Amirbeagi, Firoozeh, Kockum, Ingrid, Olsson, Tomas, Malmestrom, Clas, Lycke, Jan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061078/ https://www.ncbi.nlm.nih.gov/pubmed/37006489 http://dx.doi.org/10.3389/fneur.2023.1137665 |
Ejemplares similares
-
Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing–remitting multiple sclerosis: an observational study
por: Zhukovsky, Christina, et al.
Publicado: (2021) -
A five-year observational prospective mono-center study of the efficacy of alemtuzumab in a real-world cohort of patients with multiple sclerosis
por: Sandgren, Sofia, et al.
Publicado: (2023) -
Intrathecal kappa free light chain synthesis is associated with worse prognosis in relapsing–remitting multiple sclerosis
por: Rosenstein, Igal, et al.
Publicado: (2023) -
Inflammation-related plasma and CSF biomarkers for multiple sclerosis
por: Huang, Jesse, et al.
Publicado: (2020) -
Cerebrospinal fluid growth-associated protein 43 in multiple sclerosis
por: Sandelius, Åsa, et al.
Publicado: (2019)